Download PDF
Der Nuklearmediziner 2018; 41(03): 253-263
DOI: 10.1055/a-0621-3227
PET Update 2018
© Georg Thieme Verlag KG Stuttgart · New York

Neuro-PET – ein Update

Neuro-PET - an update
Leonie Beyer
1   Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München
,
Axel Rominger
2   Klinik für Nuklearmedizin, Inselspital, Universität Bern, Bern, Schweiz
› Author Affiliations
Further Information

Publication History

Publication Date:
07 September 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Neurologische Fragestellungen haben in der Positronen-Emissions-Tomografie seit vielen Jahren einen festen Stellenwert. In dieser Übersichtsarbeit werden in der Klinik gängige Untersuchungsmethoden bei der Demenzdiagnostik, Abklärung von Bewegungsstörungen sowie der Epilepsiediagnostik unter Berücksichtigung aktueller Leitlinien dargestellt und durch aktuelle Entwicklungen in der Wissenschaft erweitert. Ebenso wird die nuklearmedizinische Diagnostik von Hirntumoren samt theragnostischem Ausblick aufgezeigt. In einem weiteren Subkapitel wird die Entwicklung im Bereich der Neuroinflammation erläutert. Insgesamt lässt sich festhalten, dass in der Neuronuklearmedizin in den letzten Jahren einige Neuentwicklungen hervorgebracht wurden, welche sicherlich ihren Stellenwert auch in der klinischen Routine finden werden.

Abstract

Neurological investigations have an established role in positron-emission-tomography for many years. In this review, clinical routine PET procedures will be presented for diagnoses related to dementia, movement disorders and epilepsy, taking into consideration the current guidelines. Furthermore latest findings and ongoing research will be presented. Complemented by the diagnostics of brain tumors including theragnostic aspects the paper will finalize with latest developments in the field of neuroinflammation. In summary, there have been several new developments in neuro-PET in recent years, which will find their role in future clinical routine.

Schlüsselwörter

Positronen-Emissions-Tomographie - Neurodegeneration - Neuroonkologie - Neuroinflammation - Epilepsie - Radiotracer

Keywords

positron-emission-tomography - neurodegeneration - neurooncology - neuroinflammation - epilepsy - radiotracer
 

  • Literatur

  • 1 Kotzerke J, Oehme L, Lindner O. et al. [Positron emission tomography 2008 in Germany - results of the query and current status]. Nuklearmedizin Nuclear medicine 2010; 49: 58-64
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Kotzerke J, Oehme L, Grosse J. et al. [Positron emission tomography 2013 in Germany. Results of the query and current status]. Nuklearmedizin Nuclear medicine 2015; 54: 53-59
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Dilling H. Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V (F) – Klinisch-diagnostische Leitlinien. Huber Hans; 2015
    Google Scholar
  • 4 McKhann GM, Knopman DS, Chertkow H. et al. The diagnosis of dementia due to Alzheimerʼs disease: recommendations from the National Institute on Aging-Alzheimerʼs Association workgroups on diagnostic guidelines for Alzheimerʼs disease. Alzheimers Dement 2011; 7: 263-269
    CrossrefPubMedGoogle Scholar
  • 5 Dubois B, Feldman HH, Jacova C. et al. Advancing research diagnostic criteria for Alzheimerʼs disease: the IWG-2 criteria. The Lancet Neurology 2014; 13: 614-629
    CrossrefPubMedGoogle Scholar
  • 6 Leitlinie Demenzen, Entwicklungsstufe S3, 2016. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie (DGN). 2016
    PubMedGoogle Scholar
  • 7 Jack Jr CR, Bennett DA, Blennow K. et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016; 87: 539-547
    CrossrefPubMedGoogle Scholar
  • 8 Burdette JH, Minoshima S, VanderBorght T. et al. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 1996; 198: 837-843
    CrossrefPubMedGoogle Scholar
  • 9 Minoshima S, Frey KA, Koeppe RA. et al. A diagnostic approach in Alzheimerʼs disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238-1248
    PubMedGoogle Scholar
  • 10 Bloudek LM, Spackman DE, Blankenburg M. et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimerʼs disease. Journal of Alzheimerʼs disease: JAD 2011; 26: 627-645
    PubMedGoogle Scholar
  • 11 Foster NL, Heidebrink JL, Clark CM. et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimerʼs disease. Brain: a journal of neurology 2007; 130: 2616-2635
    CrossrefPubMedGoogle Scholar
  • 12 Klunk WE, Engler H, Nordberg A. et al. Imaging brain amyloid in Alzheimerʼs disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319
    CrossrefPubMedGoogle Scholar
  • 13 Villemagne VL, Mulligan RS, Pejoska S. et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimerʼs disease. Eur J Nucl Med Mol Imaging 2012; 39: 983-989
    CrossrefPubMedGoogle Scholar
  • 14 Sabri O, Sabbagh MN, Seibyl J. et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimerʼs disease: phase 3 study. Alzheimers Dement 2015; 11: 964-974
    CrossrefPubMedGoogle Scholar
  • 15 Ikonomovic MD, Buckley CJ, Heurling K. et al. Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection. Acta neuropathologica communications 2016; 4: 130
    CrossrefPubMedGoogle Scholar
  • 16 Clark CM, Pontecorvo MJ, Beach TG. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669-678
    CrossrefPubMedGoogle Scholar
  • 17 Clark CM, Schneider JA, Bedell BJ. et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275-283
    CrossrefPubMedGoogle Scholar
  • 18 Jack Jr CR, Wiste HJ, Weigand SD. et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. The Lancet Neurology 2014; 13: 997-1005
    CrossrefPubMedGoogle Scholar
  • 19 Johnson KA, Minoshima S, Bohnen NI. et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimerʼs Association. Alzheimerʼs & dementia: the journal of the Alzheimerʼs Association 2013; 9: e1-16
    PubMedGoogle Scholar
  • 20 Jessen F, Spottke A, Boecker H. et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimerʼs disease (DELCODE). Alzheimerʼs research & therapy 2018; 10: 15
    PubMedGoogle Scholar
  • 21 Budd Haeberlein S, OʼGorman J, Chiao P. et al. Clinical Development of Aducanumab, an Anti-Abeta Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimerʼs Disease. The journal of prevention of Alzheimerʼs disease 2017; 4: 255-263
    PubMedGoogle Scholar
  • 22 Brendel M, Schnabel J, Schonecker S. et al. Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. European journal of nuclear medicine and molecular imaging 2017; 44: 2239-2248
    CrossrefPubMedGoogle Scholar
  • 23 Barthel H, Sabri O. Clinical Use and Utility of Amyloid Imaging. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2017; 58: 1711-1717
    PubMedGoogle Scholar
  • 24 Hsiao IT, Huang CC, Hsieh CJ. et al. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET. European journal of nuclear medicine and molecular imaging 2013; 40: 908-920
    CrossrefPubMedGoogle Scholar
  • 25 Daerr S, Brendel M, Zach C. et al. Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases. NeuroImage Clinical 2017; 14: 77-86
    CrossrefPubMedGoogle Scholar
  • 26 Tiepolt S, Hesse S, Patt M. et al. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimerʼs disease. Eur J Nucl Med Mol Imaging 2016; 43: 1700-1709
    CrossrefPubMedGoogle Scholar
  • 27 Meyer PT, Hellwig S, Amtage F. et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med 2011; 52: 393-400
    CrossrefPubMedGoogle Scholar
  • 28 Drzezga A, Barthel H, Minoshima S. et al. Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2014; 55 (Suppl. 02) 47S-55S
    PubMedGoogle Scholar
  • 29 Barthel H, Schroeter ML, Hoffmann KT. et al. PET/MR in dementia and other neurodegenerative diseases. Seminars in nuclear medicine 2015; 45: 224-233
    CrossrefPubMedGoogle Scholar
  • 30 Werner P, Rullmann M, Bresch A. et al. Impact of attenuation correction on clinical [(18)F]FDG brain PET in combined PET/MRI. EJNMMI research 2016; 6: 47
    CrossrefPubMedGoogle Scholar
  • 31 Cecchin D, Palombit A, Castellaro M. et al. Brain PET and functional MRI: why simultaneously using hybrid PET/MR systems?. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So 2017; 61: 345-359
    PubMedGoogle Scholar
  • 32 Eggert KM. Leitlinie Parkinson-Syndrome – Diagnostik und Therapie, Entwicklungsstufe S2k, 2012. Deutsche Gesellschaft für Neurologie.
    Google Scholar
  • 33 Levin J, Kurz A, Arzberger T. et al. The Differential Diagnosis and Treatment of Atypical Parkinsonism. Deutsches Ärzteblatt international 2016; 113: 61-69
    PubMedGoogle Scholar
  • 34 Schreckenberger M, Hagele S, Siessmeier T. et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2004; 31: 1128-1135
    PubMedGoogle Scholar
  • 35 Hellwig S, Amtage F, Kreft A. et al. [(1)(8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79: 1314-1322
    CrossrefPubMedGoogle Scholar
  • 36 Mille E, Levin J, Brendel M. et al. Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome. Journal of neuroimaging: official journal of the American Society of Neuroimaging 2017; 27: 255-261
    CrossrefPubMedGoogle Scholar
  • 37 Gilman S. Functional imaging with positron emission tomography in multiple system atrophy. Journal of neural transmission (Vienna, Austria: 1996) 2005; 112: 1647-1655
    CrossrefPubMedGoogle Scholar
  • 38 Amtage F, Maurer C, Hellwig S. et al. Functional correlates of vertical gaze palsy and other ocular motor deficits in PSP: an FDG-PET study. Parkinsonism & related disorders 2014; 20: 898-906
    CrossrefPubMedGoogle Scholar
  • 39 Kikuchi A, Okamura N, Hasegawa T. et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 2016; 87: 2309-2316
    CrossrefPubMedGoogle Scholar
  • 40 Coakeley S, Cho SS, Koshimori Y. et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 2017; 37: 3150-3160
    CrossrefPubMedGoogle Scholar
  • 41 Whitwell JL, Lowe VJ, Tosakulwong N. et al. [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Movement disorders: official journal of the Movement Disorder Society 2017; 32: 124-133
    CrossrefPubMedGoogle Scholar
  • 42 Kantarci K, Lowe VJ, Boeve BF. et al. AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of neurology 2017; 81: 58-67
    CrossrefPubMedGoogle Scholar
  • 43 Smith R, Scholl M, Widner H. et al. In vivo retention of 18F-AV-1451 in corticobasal syndrome. Neurology 2017; 89: 845-853
    CrossrefPubMedGoogle Scholar
  • 44 Brendel M, Schonecker S, Hoglinger G. et al. [(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. Front Aging Neurosci 2017; 9: 440
    PubMedGoogle Scholar
  • 45 Harada R, Okamura N, Furumoto S. et al. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med 2016; 57: 208-214
    CrossrefPubMedGoogle Scholar
  • 46 Chien DT, Bahri S, Szardenings AK. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. Journal of Alzheimerʼs disease: JAD 2013; 34: 457-468
    PubMedGoogle Scholar
  • 47 Ng KP, Pascoal TA, Mathotaarachchi S. et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimerʼs research & therapy 2017; 9: 25
    PubMedGoogle Scholar
  • 48 Lemoine L, Gillberg PG, Svedberg M. et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimerʼs research & therapy 2017; 9: 96
    PubMedGoogle Scholar
  • 49 Gokdemir S, Halac M, Albayram S. et al. Contribution of FDG-PET in epilepsy surgery: consistency and postoperative results compared with magnetic resonance imaging and electroencephalography. Turkish neurosurgery 2015; 25: 53-57
    PubMedGoogle Scholar
  • 50 Fei P, Soucy JP, Obaid S. et al. The Value of Regional Cerebral Blood Flow SPECT and FDG PET in Operculoinsular Epilepsy. Clinical nuclear medicine 2018; 43: e67-e73
    CrossrefPubMedGoogle Scholar
  • 51 Hodolic M, Topakian R, Pichler R. (18)F-fluorodeoxyglucose and (18)F-flumazenil positron emission tomography in patients with refractory epilepsy. Radiology and oncology 2016; 50: 247-253
    PubMedGoogle Scholar
  • 52 Savic I, Ingvar M, Stone-Elander S. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. Journal of neurology, neurosurgery, and psychiatry 1993; 56: 615-621
    CrossrefPubMedGoogle Scholar
  • 53 Mitterhauser M, Wadsak W, Wabnegger L. et al. Biological evaluation of 2ʼ-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nuclear medicine and biology 2004; 31: 291-295
    CrossrefPubMedGoogle Scholar
  • 54 Rathore C, Dickson JC, Teotonio R. et al. The utility of 18F-fluorodeoxyglucose PET (FDG PET) in epilepsy surgery. Epilepsy research 2014; 108: 1306-1314
    CrossrefPubMedGoogle Scholar
  • 55 Scott JN, Brasher PM, Sevick RJ. et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002; 59: 947-949
    CrossrefPubMedGoogle Scholar
  • 56 Ostrom QT, Gittleman H, Liao P. et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-oncology 2017; 19 (Suppl. 05) v1-v88
    PubMedGoogle Scholar
  • 57 la Fougere C, Suchorska B, Bartenstein P. et al. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-oncology 2011; 13: 806-819
    PubMedGoogle Scholar
  • 58 Thomas DG, Beaney RP, Brooks DJ. Positron emission tomography in the study of cerebral tumours. Neurosurgical review 1984; 7: 253-258
    CrossrefPubMedGoogle Scholar
  • 59 Ericson K, Lilja A, Bergstrom M. et al. Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. Journal of computer assisted tomography 1985; 9: 683-689
    CrossrefPubMedGoogle Scholar
  • 60 Heiss WD, Wienhard K, Wagner R. et al. F-Dopa as an amino acid tracer to detect brain tumors. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 1996; 37: 1180-1182
    PubMedGoogle Scholar
  • 61 Albert NL, Weller M, Suchorska B. et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-oncology 2016; 18: 1199-1208
    PubMedGoogle Scholar
  • 62 Rapp M, Heinzel A, Galldiks N. et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2013; 54: 229-235
    PubMedGoogle Scholar
  • 63 Hutterer M, Nowosielski M, Putzer D. et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-oncology 2013; 15: 341-351
    PubMedGoogle Scholar
  • 64 Dunet V, Pomoni A, Hottinger A. et al. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro-oncology 2016; 18: 426-434
    PubMedGoogle Scholar
  • 65 Jansen NL, Graute V, Armbruster L. et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?. European journal of nuclear medicine and molecular imaging 2012; 39: 1021-1029
    CrossrefPubMedGoogle Scholar
  • 66 Pafundi DH, Laack NN, Youland RS. et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro-oncology 2013; 15: 1058-1067
    PubMedGoogle Scholar
  • 67 Grosu AL, Weber WA, Riedel E. et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. International journal of radiation oncology, biology, physics 2005; 63: 64-74
    CrossrefPubMedGoogle Scholar
  • 68 Suchorska B, Jansen NL, Linn J. et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 2015; 84: 710-719
    CrossrefPubMedGoogle Scholar
  • 69 Ewelt C, Floeth FW, Felsberg J. et al. Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clinical neurology and neurosurgery 2011; 113: 541-547
    CrossrefPubMedGoogle Scholar
  • 70 Kumar AJ, Leeds NE, Fuller GN. et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000; 217: 377-384
    CrossrefPubMedGoogle Scholar
  • 71 Galldiks N, Dunkl V, Stoffels G. et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. European journal of nuclear medicine and molecular imaging 2015; 42: 685-695
    CrossrefPubMedGoogle Scholar
  • 72 Galldiks N, Stoffels G, Filss C. et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-oncology 2015; 17: 1293-1300
    PubMedGoogle Scholar
  • 73 Wyss M, Hofer S, Bruehlmeier M. et al. Early metabolic responses in temozolomide treated low-grade glioma patients. Journal of neuro-oncology 2009; 95: 87-93
    CrossrefPubMedGoogle Scholar
  • 74 Colavolpe C, Chinot O, Metellus P. et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro-oncology 2012; 14: 649-657
    PubMedGoogle Scholar
  • 75 Singhal T, Narayanan TK, Jacobs MP. et al. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2012; 53: 1709-1715
    PubMedGoogle Scholar
  • 76 Jansen NL, Suchorska B, Wenter V. et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2014; 55: 198-203
    PubMedGoogle Scholar
  • 77 Galldiks N, Stoffels G, Filss CP. et al. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2012; 53: 1367-1374
    PubMedGoogle Scholar
  • 78 Glaudemans AW, Enting RH, Heesters MA. et al. Value of 11C-methionine PET in imaging brain tumours and metastases. European journal of nuclear medicine and molecular imaging 2013; 40: 615-635
    CrossrefPubMedGoogle Scholar
  • 79 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica 2016; 131: 803-820
    CrossrefPubMedGoogle Scholar
  • 80 Goldbrunner R, Minniti G, Preusser M. et al. EANO guidelines for the diagnosis and treatment of meningiomas. The Lancet Oncology 2016; 17: e383-391
    CrossrefPubMedGoogle Scholar
  • 81 Dutour A, Kumar U, Panetta R. et al. Expression of somatostatin receptor subtypes in human brain tumors. International journal of cancer 1998; 76: 620-627
    CrossrefPubMedGoogle Scholar
  • 82 Reubi JC, Maurer R, Klijn JG. et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. The Journal of clinical endocrinology and metabolism 1986; 63: 433-438
    CrossrefPubMedGoogle Scholar
  • 83 Rachinger W, Stoecklein VM, Terpolilli NA. et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2015; 56: 347-353
    PubMedGoogle Scholar
  • 84 Afshar-Oromieh A, Giesel FL, Linhart HG. et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET/CT and contrast-enhanced MRI. European journal of nuclear medicine and molecular imaging 2012; 39: 1409-1415
    CrossrefPubMedGoogle Scholar
  • 85 Chatalic KL, Kwekkeboom DJ, de Jong M. Radiopeptides for Imaging and Therapy: A Radiant Future. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2015; 56: 1809-1812
    PubMedGoogle Scholar
  • 86 Seystahl K, Stoecklein V, Schuller U. et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro-oncology 2016; 18: 1538-1547
    PubMedGoogle Scholar
  • 87 Unterrainer M, Niyazi M, Ruf V. et al. The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?. Neuro-oncology 2017; 19: 1698-1699
    PubMedGoogle Scholar
  • 88 Albrecht DS, Granziera C, Hooker JM. et al. In Vivo Imaging of Human Neuroinflammation. ACS chemical neuroscience 2016; 7: 470-483
    CrossrefPubMedGoogle Scholar
  • 89 Feeney C, Scott G, Raffel J. et al. Kinetic analysis of the translocator protein positron emission tomography ligand [(18)F]GE-180 in the human brain. European journal of nuclear medicine and molecular imaging 2016; 43: 2201-2210
    CrossrefPubMedGoogle Scholar
  • 90 Liu GJ, Middleton RJ, Hatty CR. et al. The 18 kDa translocator protein, microglia and neuroinflammation. Brain pathology (Zurich, Switzerland) 2014; 24: 631-653
    CrossrefPubMedGoogle Scholar
  • 91 Tu LN, Morohaku K, Manna PR. et al. Peripheral benzodiazepine receptor/translocator protein global knock-out mice are viable with no effects on steroid hormone biosynthesis. The Journal of biological chemistry 2014; 289: 27444-27454
    CrossrefPubMedGoogle Scholar
  • 92 Turkheimer FE, Rizzo G, Bloomfield PS. et al. The methodology of TSPO imaging with positron emission tomography. Biochemical Society transactions 2015; 43: 586-592
    CrossrefPubMedGoogle Scholar
  • 93 Wadsworth H, Jones PA, Chau WF. et al. [(1)(8)F]GE-180: a novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO). Bioorganic & medicinal chemistry letters 2012; 22: 1308-1313
    CrossrefPubMedGoogle Scholar
  • 94 Vomacka L, Albert NL, Lindner S. et al. TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI research 2017; 7: 89
    CrossrefPubMedGoogle Scholar
  • 95 Albert NL, Unterrainer M, Fleischmann DF. et al. TSPO PET for glioma imaging using the novel ligand (18)F-GE-180: first results in patients with glioblastoma. European journal of nuclear medicine and molecular imaging 2017; 44: 2230-2238
    CrossrefPubMedGoogle Scholar
  • 96 Heneka MT, Carson MJ, El Khoury J. et al. Neuroinflammation in Alzheimerʼs disease. The Lancet Neurology 2015; 14: 388-405
    CrossrefPubMedGoogle Scholar
  • 97 Brendel M, Focke C, Blume T. et al. Time Courses of Cortical Glucose Metabolism and Microglial Activity Across the Life Span of Wild-Type Mice: A PET Study. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2017; 58: 1984-1990
    PubMedGoogle Scholar
  • 98 Brendel M, Kleinberger G, Probst F. et al. Increase of TREM2 during Aging of an Alzheimerʼs Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. Frontiers in aging neuroscience 2017; 9: 8
    PubMedGoogle Scholar
  • 99 Brendel M, Probst F, Jaworska A. et al. Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2016; 57: 954-960
    PubMedGoogle Scholar
  • 100 Kreisl WC, Henter ID, Innis RB. Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. Advances in pharmacology (San Diego, Calif) 2018; 82: 163-185
    PubMedGoogle Scholar
  • 101 Stefaniak J, OʼBrien J. Imaging of neuroinflammation in dementia: a review. Journal of neurology, neurosurgery, and psychiatry 2016; 87: 21-28
    CrossrefPubMedGoogle Scholar
  • 102 Spillantini MG. Parkinsonʼs disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism & related disorders 1999; 5: 157-162
    CrossrefPubMedGoogle Scholar
  • 103 Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta neuropathologica 2017; 134: 187-205
    CrossrefPubMedGoogle Scholar
  • 104 Fodero-Tavoletti MT, Mulligan RS, Okamura N. et al. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. European journal of pharmacology 2009; 617: 54-58
    CrossrefPubMedGoogle Scholar
  • 105 Kikuchi A, Takeda A, Okamura N. et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain: a journal of neurology 2010; 133: 1772-1778
    CrossrefPubMedGoogle Scholar
  • 106 Zhang X, Jin H, Padakanti PK. et al. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging alpha-Synuclein. Applied sciences (Basel, Switzerland) 2014; 4: 66-78
    CrossrefPubMedGoogle Scholar
  • 107 Chu W, Zhou D, Gaba V. et al. Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for alpha-Synuclein Fibrils. Journal of medicinal chemistry 2015; 58: 6002-6017
    CrossrefPubMedGoogle Scholar
  • 108 Gao J, Wang L, Huntley ML. et al. Pathomechanisms of TDP-43 in neurodegeneration. Journal of neurochemistry DOI: 10.1111/jnc.14327.
    PubMedGoogle Scholar